Condition

CNS Tumor

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting1

Common interventions11

Lead sponsors shown3

Clinical trials

3 shown

A Study of PHST001 in Advanced Solid TumorsNCT06840886 · 2025-03-31

RECRUITING

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast AgentNCT06322342 · 2024-08-15

COMPLETED

Effectiveness of Care in Certified Cancer Centres in GermanyNCT04334239 · 2017-05-01

COMPLETED

Common interventions

DoxorubicinDRUG1 FOLFIRIDRUG1 FOLFOXDRUG1 GemcitabineDRUG1 Mirvetuximab SoravtansineBIOLOGICAL1 Oncological certificationOTHER1 PaclitaxelDRUG1 PHST001BIOLOGICAL1 RVP-001DRUG1 TopotecanDRUG1 Trastuzumab DeruxtecanBIOLOGICAL1

Mapped drugs appearing in these trials

Shared trial participation only; not evidence of efficacy or approval.

doxorubicin1 gemcitabine1 paclitaxel1 topotecan1

Leading sponsors

Pheast Therapeutics 1 Reveal Pharmaceuticals Inc. 1 Technische Universität Dresden 1

Trial status mix

COMPLETED2

RECRUITING1

Phase mix

PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.